4-(4-amino-2,6-dibromophenoxy)-2-isopropylphenol | 355129-22-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-amino-2,6-dibromophenoxy)-2-isopropylphenol
• 英文别名: 4-(4-amino-2,6-dibromophenoxy)-2-propan-2-ylphenol
• CAS: 355129-22-5
• 化学式: C₁₅H₁₅Br₂NO₂
• 分子量: 401.098
• InChiKey: FFSNAQRPDKMGAD-UHFFFAOYSA-N

物化性质

• 沸点：
  441.2±45.0 °C(Predicted)
• 密度：
  1.649±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-amino-2,6-dibromophenoxy)-2-isopropylphenol 在 sodium hydroxide 作用下， 以 甲基叔丁基醚 、 水 为溶剂， 反应 5.0h， 生成 4-((3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)amino)-4-oxobutanoic acid
  参考文献：
  名称：

  Rational Design of Potent and Selective Inhibitors of an Epoxide Hydrolase Virulence Factor from Pseudomonas aeruginosa

  摘要：

  The virulence factor cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif) is secreted by Pseudomonas aeruginosa and is the founding member of a distinct class of epoxide hydrolases (EHs) that triggers the catalysis-dependent degradation of the CFTR. We describe here the development of a series of potent and selective Cif inhibitors by structure-based drug design. Initial screening revealed la (KB2115), a thyroid hormone analog, as a lead compound with low micromolar potency. Structural requirements for potency were systematically probed, and interactions between Cif and la were characterized by X-ray crystallography. On the basis of these data, new compounds were designed to yield additional hydrogen bonding with residues of the Cif active site. From this effort, three compounds were identified that are 10-fold more potent toward Cif than our first-generation inhibitors and have no detectable thyroid hormone-like activity. These inhibitors will be useful tools to study the pathological role of Cif and have the potential for clinical application.

  DOI：

  10.1021/acs.jmedchem.6b00173
• 作为产物：
  描述：

  2-异丙基苯甲醚 在 sodium dithionite 、 双氧水 、 三溴化硼 、 对甲苯磺酸 、 sodium hydrogensulfite 、 sodium hydroxide 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-(4-amino-2,6-dibromophenoxy)-2-isopropylphenol
  参考文献：
  名称：

  Rational Design of Potent and Selective Inhibitors of an Epoxide Hydrolase Virulence Factor from Pseudomonas aeruginosa

  摘要：

  The virulence factor cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif) is secreted by Pseudomonas aeruginosa and is the founding member of a distinct class of epoxide hydrolases (EHs) that triggers the catalysis-dependent degradation of the CFTR. We describe here the development of a series of potent and selective Cif inhibitors by structure-based drug design. Initial screening revealed la (KB2115), a thyroid hormone analog, as a lead compound with low micromolar potency. Structural requirements for potency were systematically probed, and interactions between Cif and la were characterized by X-ray crystallography. On the basis of these data, new compounds were designed to yield additional hydrogen bonding with residues of the Cif active site. From this effort, three compounds were identified that are 10-fold more potent toward Cif than our first-generation inhibitors and have no detectable thyroid hormone-like activity. These inhibitors will be useful tools to study the pathological role of Cif and have the potential for clinical application.

  DOI：

  10.1021/acs.jmedchem.6b00173

文献信息

• DRUG DERIVATIVES
  申请人：Craighead Mark

  公开号：US20130225594A1

  公开（公告）日：2013-08-29

  The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more reactions which may be considered to represent a change of oxidation state. We refer to these compounds generally as redox derivatives. The derivatives of the invention may be related to the original parent active pharmaceutical compound by only a single step transformation, or may be related via several synthetic steps including one or more changes of oxidation state. In certain cases, the functional group obtained after two or more transformations may be in the same oxidation state as the parent active compound (and we include these compounds in our definition of redox derivatives). In other cases, the oxidation state of the derivative of the invention may be regarded as being different from that of the parent compound. In many cases, the compounds of the invention have inherent therapeutic activity on their own account. In some cases, this activity relative to the same target or targets of the parent compound is as good as or better than the activity which the parent compound has against the target or targets.

  本发明涉及已知活性药物化合物的衍生物。这些衍生物通过是活性化合物的氧化还原衍生物与母体活性化合物相区别。这意味着活性化合物中的一个或多个官能团已转化为另一组，在一项或多项反应中，这可以被认为代表氧化态的变化。我们通常将这些化合物称为氧化还原衍生物。发明中的衍生物可能与原始母体活性药物化合物仅通过单一步骤转换有关，或者可能通过包括一个或多个氧化态变化的几个合成步骤与之相关。在某些情况下，经过两个或更多转换后获得的官能团可能与母体活性化合物处于相同的氧化态（我们将这些化合物包括在我们的氧化还原衍生物定义中）。在其他情况下，发明的衍生物的氧化态可以被认为是与母体化合物不同的。在许多情况下，发明中的化合物本身就具有固有的治疗活性。在某些情况下，相对于母体化合物的相同靶点或靶点，这种活性与母体化合物针对该靶点或靶点的活性一样好或更好。
• Process for the preparation of aniline-derived thyroid receptor ligands
  申请人：——

  公开号：US20030157671A1

  公开（公告）日：2003-08-21

  Provided are processes for the synthesis of aniline derivatives, specifically certain aniline derivatives which have activity as thyroid receptor ligands.

  提供了合成苯胺衍生物的过程，具体来说是具有甲状腺受体配体活性的某些苯胺衍生物。
• [EN] DRUG DERIVATIVES<br/>[FR] DÉRIVÉS DE MÉDICAMENTS
  申请人：REDX PHARMA LTD

  公开号：WO2012063085A3

  公开（公告）日：2012-08-02
• US6806381B2
  申请人：——

  公开号：US6806381B2

  公开（公告）日：2004-10-19
• US7956214B2
  申请人：——

  公开号：US7956214B2

  公开（公告）日：2011-06-07